Curated news and analysis on clinical trials, drug approvals, and medical research.
Researchers at UC San Francisco discovered that exercise triggers liver production of GPLD1, which removes TNAP protein buildup from blood-brain barrier cells, reducing age-related leakiness and cognitive decline.
Lynch syndrome patients gain access to prevention vaccines in clinical trials, while immunotherapy advances depend on universal tumor testing for microsatellite instability. Cancer vaccines are moving from research to clinical reality.
Hyderabad-based CRDMO Sai Life Sciences plans to recruit over 700 scientific, technical, and management professionals during 2026-27, representing a 20% workforce expansion driven by growing global demand for integrated drug discovery and manufacturing services.
Iovance Biotherapeutics reported Q4 2025 revenue of $87 million, beating estimates, while receiving FDA fast-track designation for lifileucel in non-small cell lung cancer and reporting strong sarcoma trial data.
New research from Michigan State University reveals that differences in hormone-regulated monocytes explain why women experience longer-lasting chronic pain than men, with males producing more IL-10 to shut down pain signals.
Oral semaglutide and the newly FDA-approved Wegovy pill are reshaping weight management by eliminating injections. Clinical trials show meaningful weight loss, while companies integrate the medications into subscription wellness programs.
A once-daily single-tablet combination of bictegravir and lenacapavir demonstrated non-inferiority to existing HIV treatments in Phase 3 trials, offering simplified treatment for people living with HIV who are virologically suppressed.
Approved gene-editing therapies for sickle cell disease priced at $2.2 million remain out of reach in Africa, where 80% of the world's cases occur, as Uganda launches mandatory newborn screening.
The University of Colorado Anschutz School of Medicine rose to No. 21 nationally with nearly $314 million in NIH funding, while Colorado School of Public Health climbed to No. 17 with over $22 million. Wayne State University School of Medicine ranked 73rd with $61.6 million.
AusBiotech signed an MOU with Proto Axiom for a coordinated 2026 investor-focused event calendar. It also expanded its Medicines Australia partnership for women’s leadership events in Sydney.
Drug candidates designed via generative artificial intelligence are achieving a 90% success rate in Phase I safety trials in early 2026, nearly double the historical industry average of approximately 50%, while compressing development timelines from six years to under 18 months.
The FDA issued early alerts for three medical device safety issues: Abiomed heart pump purge cassettes with leak risks, Trividia blood glucose monitors with misleading error instructions, and Medline homecare beds with fire and entrapment hazards.
Rare disease drug developers face significant funding challenges as traditional investment models prioritize larger patient populations, while diagnostic delays prevent patients from accessing emerging therapies including gene therapies that have reached approval in recent years.
Researchers developed pancreatic-targeted lipid nanoparticles (AH-LNP) that enable precise mRNA delivery to the pancreas through capsule-filter-mediated accumulation. The platform demonstrated efficacy in genome editing and cancer immunotherapy across multiple animal models including non-human primates.
Longeveron Inc. announced Phase 2b clinical trial results published in Cell Stem Cell showing laromestrocel improved physical condition in patients with age-related frailty after nine months compared to placebo.
A clinical trial shows baduanjin, a traditional Chinese mind-body practice, reduces blood pressure by 3-5 points, comparable to first-line medications and brisk walking, with effects sustained for one year.
The FDA has approved a new monthly dosing schedule for Johnson & Johnson's Rybrevant Faspro combined with Lazcluze for first-line treatment of advanced EGFR-mutated non-small cell lung cancer, allowing patients to transition to monthly dosing as early as week five.
The global stem cell therapy market is projected to grow from $18.13 billion in 2025 to $59.70 billion by 2035 at a 12.66% CAGR, driven by chronic disease prevalence and regenerative medicine advances.
A Lancet study of 1.1 million people found that 65% of those initially hesitant about COVID-19 vaccines went on to get vaccinated, with concerns about mRNA technology and safety declining as evidence accumulated during the rollout.
Cellectar Biosciences said it will report full-year 2025 financial results and provide a corporate update on March 4, 2026. The company also shared conference call, webcast, and replay details.
